共 99 条
[1]
Mascelli M.A.(2007)Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development J Clin Pharmacol 47 553-65
[2]
Zhou H.(2008)Monoclonal antibody pharmacokinetics and pharmacodynamics Clin Pharmacol Ther 84 548-58
[3]
Sweet R.(2006)Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 355 1018-28
[4]
Wang W.(2007)The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics Drug Discov Today 12 1018-24
[5]
Wang E.Q.(2009)Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics Br J Clin Pharmacol 67 153-60
[6]
Balthasar J.P.(2007)Preclinical and clinical safety of monoclonal antibodies Drug Discov Today 12 540-7
[7]
Suntharalingam G.(2009)Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies Clin Pharmacol Ther 85 247-58
[8]
Perry M.R.(2004)Antibody pharmacokinetics and pharmacodynamics J Pharm Sci 93 2645-68
[9]
Ward S.(2007)The pharmacokinetics and pharmacodynamics of monoclonal antibodies: mechanistic modeling applied to drug development Curr Opin Drug Discov Devel 10 84-96
[10]
Agoram B.M.(1966)The transimission of immunity from mother to young and the catabolism of immunoglobulins Lancet 2 1087-93